Trends of pre-treatment drug resistance in antiretroviral-naïve people with HIV-1 in the era of second-generation integrase strand-transfer inhibitors in Taiwan

Guan-Jhou Chen,Chien-Yu Cheng,Chia-Jui Yang,Nan-Yao Lee,Hung-Jen Tang,Sung-Hsi Huang,Miao-Hui Huang,Bo-Huang Liou,Yi-Chieh Lee,Chi-Ying Lin,Tung-Che Hung,Shih-Ping Lin,Hsin-Yun Sun,Sui-Yuan Chang,Chien-Ching Hung,Chien-Ching Hung,Sui-Yuan Chang,Hsin-Yun Sun,Yu-Shan Huang,Kuan-Yin Lin,Guan-Jhou Chen,Pei-Ying Wu,Ling-Ya Chen,Hsi-Yen Chang,Wen-Chun Liu,Yi-Ching Su,Ning-Chi Wang,Te-Yu Lin,Chia-Jui Yang,Mao-Song Tsai,Mei-Hui Lee,Yi-Chieh Lee,Shu-Hsing Cheng,Chien-Yu Cheng,Bo-Huang Liou,Sung-Hsi Huang,Yi-Chia Huang,An-Ting Peng,Yuan-Ti Lee,Yu-Lin Lee,Chia-Chun Lin,Shih-Ping Lin,Chia-Yin Hsieh,Hsiu-Wen Wang,Mao-Wang Ho,Chun-Eng Liu,Ing-Moi Hii,Chi-Ying Lin,Hung-Jen Tang,Nan-Yao Lee,Chin-Shiang Tsai,Tung-Che Hung,Yen-Hsu Chen,Po-Liang Lu,Chun-Yuan Lee,Tun-Chieh Chen,Hung-Chin Tsai,Hsi-Hsun Lin,Chen-Hsiang Lee,

DOI: https://doi.org/10.1093/jac/dkae086

2024-03-28

Journal of Antimicrobial Chemotherapy

Abstract:Abstract Background Monitoring the trends of pre-treatment drug resistance (PDR) and resistance-associated mutations (RAMs) among antiretroviral-naïve people with HIV (PWH) is important for the implementation of HIV treatment and control programmes. We analysed the trends of HIV-1 PDR after the introduction of second-generation integrase strand-transfer inhibitors (INSTIs) in 2016 in Taiwan, when single-tablet regimens of non-nucleoside reverse-transcriptase inhibitor (NNRTI-) and INSTI-based antiretroviral therapy became the preferred treatments. Materials and methods In this multicentre study, we included newly diagnosed, antiretroviral-naïve PWH who underwent tests for RAMs between 2016 and 2022. Pre-treatment genotypic resistance testing was performed, along with HIV-1 subtyping and determinations of plasma HIV RNA load and CD4 lymphocyte counts. RAMs were analysed using the Stanford University HIV Drug Resistance Database and only RAMs conferring at least low-level resistance were included. Results From 2016 to 2022, pre-treatment blood samples from 3001 newly diagnosed PWH, which constituted 24.3% of newly diagnosed PWH in Taiwan during the study period, were tested. Of the PWH with analysable gene sequences, the HIV-1 PDR prevalence to NNRTIs, nucleoside reverse-transcriptase inhibitors (NRTIs), first- and second-generation INSTIs and PIs was 10.0%, 2.1%, 2.5%, 0.6% and 0.4%, respectively. While the trends of PDR remained stable for NRTIs, INSTIs and PIs, there was a significantly increasing trend of PDR to NNRTIs from 6.0% in 2016% to 13.1% in 2022 (P = 0.001). Conclusions After the introduction of second-generation INSTIs in Taiwan, the trends of HIV-1 PDR to NRTIs and INSTIs remained low. Furthermore, there was no significant decrease of the prevalence of PDR toward NNRTIs between 2016 and 2022.

pharmacology & pharmacy,infectious diseases,microbiology